.navbar .collapse { display: block; } .mobile-nav { max-height: none !important; } @media screen and (min-width: 1200px) { .navbar #basic-navbar-nav .navbar-nav { position: static !important; } }

Spotlight

OncClub: Join the Chat on Trending Trials in Cancer
AML: Evolving Perspectives on Testing, Therapies, & Transplantation
BCMA as a Target in Heavily Pretreated Multiple Myeloma
Expanding Treatment Options for HER2+ Breast Cancer
The Next Steps for CAR T-Cell Therapy in DLBCL

SpecialtySee All >

Biosimilars
Breast Cancer
Gastrointestinal Cancer
Genitourinary Cancers
Gynecologic Oncology
Head & Neck Cancers
Hematologic Oncology
Immuno-Oncology
Lung Cancer
Melanoma & Skin Cancer
Multiple Myeloma

Advertise
About OncLive
Editorial Board
CureToday.com
TargetedOnc.com
CancerNetwork.com
Contact Us
Privacy
Terms & Conditions
Do Not Sell My Information

2 Clarke Drive
Suite 100
Cranbury, NJ 08512

Expanding Treatment Options for HER2+ Breast Cancer

EP. 1: Guidelines and Approaches to HER2 Testing for Breast Cancer

June 30th 2020

EP. 2: HER2+ Early-Stage Breast Cancer

June 30th 2020

EP. 3: APHINITY and ExteNET Trials for Early-Stage Breast Cancer

June 30th 2020

EP. 4: TRAIN-2: Anthracyclines in HER2+ Breast Cancer

June 30th 2020

EP. 5: KAITLIN: T-DM1/Pertuzumab After Anthracycline-Based Adjuvant Therapy

June 30th 2020

EP. 6: HER2+ Early Stage Breast Cancer With Residual Invasive Disease

June 30th 2020

EP. 7: Biomarker Data After Neoadjuvant Therapy for HER2+ Breast Cancer

June 30th 2020

EP. 8: HER2CLIMB: Brain Metastases Data

June 30th 2020

EP. 9: Treatment Choice for Patient Relapsing With Brain Metastases

June 30th 2020

EP. 10: DS-8201 and Tucatinib in HER2+ Metastatic Breast Cancer

June 30th 2020